Skip To Main Content
This website is intended exclusively for healthcare professionals residing and/or working in the UAE.
Campus
  • Payor
Campus
  • Payor

SoliMix Study Results Summary

Discover clinical outcomes with iGlarLixi versus Premix BIAsp 30 in the SoliMix Randomized Controlled Trial leading to advancing therapy in sub-optimally controlled basal insulin-treated Type-2 diabetes.

Related articles
EMPOWER Study in Saudi Arabia

EMPOWER Study in Saudi Arabia

Key highlights from the EMPOWER Study in Saudi Arabia

Read article
Advancing Therapy with iGlarLixi: Differentiation from complex insulin regimens

Advancing Therapy with iGlarLixi: Differentiation from complex insulin regimens

Read article
Advancing Therapy with iGlarLixi: Differentiation from other complex regimens

Advancing Therapy with iGlarLixi: Differentiation from other complex regimens

Read article
MAT-BH-2300623/v1/November2023